Rr. Tamesis et al., SYSTEMIC DRUG TOXICITY TRENDS IN IMMUNOSUPPRESSIVE THERAPY OF IMMUNE AND INFLAMMATORY OCULAR DISEASE, Ophthalmology, 103(5), 1996, pp. 768-775
Purpose: To compare the relative toxicities of six systemic immunosupp
ressive drugs and systemic corticosteroids used to treat patients with
severe ocular inflammatory disease and to identify factors influencin
g their occurrence. Methods: The authors reviewed the clinical records
of 602 patients with ocular inflammatory disease treated with immunos
uppressive drug therapy and/or systemic corticosteroids for adverse sy
stemic effects while undergoing therapy. Proportional hazards regressi
on analysis was performed to identify demographic and clinical factors
that influence the occurrence of drug toxicity in these patients. Res
ults: Immunosuppressive drug treatment was more likely to result in di
scontinuation of therapy because of toxic side effects than was cortic
osteroid treatment. However, unlike many of the side effects of cortic
osteroid treatment, the side effects of immunosuppressive therapy were
reversible with reduction in dosage or discontinuation of the drug. G
astrointestinal symptoms and hematologic abnormalities accounted for t
he majority of reported side effects of the immunosuppressive medicati
ons. Neuropsychiatric and endocrine side effects were common in patien
ts taking prednisone. In 17 patients treated with prednisone, patholog
ic fractures developed, which involved the hips and the spine. Female
sex and age older than 60 years also were identified as factors associ
ated with intolerance to drug therapy in the authors' study population
. Race and type of systemic and ocular disease were not significant fa
ctors influencing tolerance to drug therapy. Conclusion: These finding
s suggest that when properly administered and monitored for adverse ef
fects, most immunosuppressive agents used in the current study have si
milar risk profiles with relatively few serious therapeutic mishaps an
d largely reversible side effects. In contrast, corticosteroids can re
sult in permanent disabilities as a result of long-term treatment.